血清组织 SIRT1 作为胃癌有潜力的生物标志物。

Serum Tissue SIRT1 as Potentially Valuable Biomarkers in Gastric Cancer.

机构信息

Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan

Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

出版信息

Anticancer Res. 2023 Apr;43(4):1485-1491. doi: 10.21873/anticanres.16297.

DOI:10.21873/anticanres.16297

PMID:36974791

Abstract

BACKGROUND/AIM: We lack reports on the clinicopathological characteristics and prognostic value of serum sirtuin 1 (SIRT1) levels and their association with SIRT1 expression in tissues of patients with gastric cancer (GC). Thus, we investigated the pathological characteristics and prognostic values of SIRT1 tissue expression and its serum concentration in GC. Moreover, we investigated the correlation between these two factors.

MATERIALS AND METHODS

A total of 78 patients with GC who underwent curative gastrectomy were evaluated in this study. The expression of SIRT1 in the surgical specimens was assessed using immunohistochemistry. Serum levels of SIRT1 were measured using an enzyme-linked immunosorbent assay. The association of tissue and serum SIRT1 with the clinicopathological features and prognosis were evaluated.

RESULTS

Positive SIRT1 tissue expression was significantly related to an advanced cancer stage (p=0.017). Furthermore, a significant relationship existed between a positive SIRT1 tissue expression and poorer overall survival (OS) and relapse-free survival (RFS) (p=0.033 and p=0.033, respectively). In contrast, serum SIRT1 levels showed no significant association with clinicopathological characteristics besides age. In addition, no significant correlation was observed between tissue SIRT1 expression and serum SIRT1 concentration.

CONCLUSION

Tissue SIRT1 expression may be a valuable novel prognostic biomarker; nonetheless, further studies are required to clarify the relationship between tissue SIRT1 expression and serum SIRT1 levels in GC.

摘要

背景/目的：我们缺乏关于血清沉默信息调节因子 1（SIRT1）水平及其与胃癌（GC）组织中 SIRT1 表达的临床病理特征和预后价值的报告。因此，我们研究了 SIRT1 组织表达及其在 GC 中的血清浓度的病理特征和预后价值。此外，我们还研究了这两个因素之间的相关性。

材料和方法

本研究共评估了 78 例接受根治性胃切除术的 GC 患者。使用免疫组织化学评估手术标本中 SIRT1 的表达。使用酶联免疫吸附试验测量 SIRT1 的血清水平。评估组织和血清 SIRT1 与临床病理特征和预后的相关性。

结果

阳性 SIRT1 组织表达与晚期癌症分期显著相关（p=0.017）。此外，SIRT1 组织阳性表达与总生存期（OS）和无复发生存期（RFS）较差显著相关（p=0.033 和 p=0.033）。相比之下，血清 SIRT1 水平除了年龄外，与临床病理特征无显著相关性。此外，组织 SIRT1 表达与血清 SIRT1 浓度之间未观察到显著相关性。